Biostar Pharmaceuticals, Inc. (BSPM) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biostar Pharmaceuticals, Inc. (BSPM) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 47/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Biostar Pharmaceuticals, Inc. (BSPM) Resumen de Asistencia Médica y Tuberías
Biostar Pharmaceuticals, Inc., based in China, develops and markets OTC and prescription pharmaceutical products, including its key product Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B. The company distributes its products across 28 provinces in China, leveraging both distributors and a direct sales network.
Tesis de Inversión
Biostar Pharmaceuticals operates in the Chinese pharmaceutical market, focusing on both OTC and prescription drugs. The company's key product, Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B, addresses a significant health issue in China. However, with a negative profit margin of -239.0% and a market capitalization of $0.00B, the company faces significant financial challenges. Potential growth catalysts include expanding its product line and increasing its market penetration within China. Investors should carefully consider the risks associated with investing in OTC-listed companies, including liquidity and disclosure concerns.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross Margin of 38.4% indicates potential for profitability if costs are managed effectively.
- Operates in 28 provinces in China, demonstrating a significant distribution network.
- Offers both OTC and prescription drugs, diversifying its revenue streams.
- Key product, Xin Ao Xing Oleanolic Acid capsule, targets chronic hepatitis B, a significant health issue in China.
- Profit Margin of -239.0% signals financial challenges requiring strategic intervention.
Competidores y Pares
Fortalezas
- Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
Debilidades
- Negative profit margin.
- Limited financial resources.
- Dependence on a single key product (Xin Ao Xing).
- OTC listing indicates higher risk.
Catalizadores
- Upcoming: Potential regulatory approvals for new pharmaceutical products.
- Ongoing: Expansion of the company's distribution network in China.
- Ongoing: Increased adoption of the China Hepatitis Internet hospital platform.
Riesgos
- Potential: Competition from larger pharmaceutical companies.
- Potential: Regulatory changes in China.
- Ongoing: Fluctuations in raw material prices.
- Ongoing: Economic slowdown in China.
- Ongoing: Negative profit margin and limited financial resources.
Oportunidades de crecimiento
- Expanding its OTC product line: Biostar can capitalize on the growing demand for OTC medications in China by introducing new products targeting common ailments. The Chinese OTC market is projected to reach $50 billion by 2028, offering significant revenue potential. Timeline: Launching 2-3 new OTC products annually over the next 3-5 years could significantly boost revenue.
- Increasing market penetration in existing provinces: Biostar currently operates in 28 provinces in China. Deepening its market penetration within these regions through targeted marketing and sales initiatives can drive revenue growth. The pharmaceutical market in these provinces is estimated at $200 billion, offering ample opportunity for expansion. Timeline: Achieving a 1% increase in market share in each province over the next 2 years.
- Leveraging its online platform: Biostar's China Hepatitis Internet hospital provides a direct channel to reach HBV patients. Expanding the platform's services and offerings, such as online consultations and prescription refills, can enhance customer engagement and drive sales. The online healthcare market in China is projected to reach $40 billion by 2027. Timeline: Expanding online services and increasing user engagement by 20% annually.
- Developing new prescription drugs: Biostar can invest in research and development to create new prescription drugs targeting unmet medical needs in China. The prescription drug market in China is projected to reach $300 billion by 2028. Timeline: Launching 1-2 new prescription drugs every 3 years.
- Strategic partnerships and acquisitions: Biostar can explore strategic partnerships or acquisitions to expand its product portfolio, market reach, and technological capabilities. The Chinese pharmaceutical market is consolidating, presenting opportunities for strategic alliances. Timeline: Pursuing 1-2 strategic partnerships or acquisitions over the next 5 years.
Oportunidades
- Expanding OTC product line.
- Increasing market penetration in existing provinces.
- Leveraging online platform for growth.
- Developing new prescription drugs.
Amenazas
- Competition from larger pharmaceutical companies.
- Regulatory changes in China.
- Fluctuations in raw material prices.
- Economic slowdown in China.
Ventajas competitivas
- Established distribution network in 28 provinces in China.
- Focus on traditional Chinese medicine.
- Key product targeting chronic hepatitis B, a significant health issue in China.
- Online platform providing direct access to HBV patients.
Acerca de BSPM
Biostar Pharmaceuticals, Inc., established in 2007 and headquartered in Xianyang, China, is engaged in the development, manufacture, and marketing of pharmaceutical products. The company's portfolio includes both over-the-counter (OTC) and prescription medications, addressing a variety of diseases and conditions prevalent in the Chinese market. Its primary product is Xin Ao Xing Oleanolic Acid capsule, an OTC medicine indicated for chronic hepatitis B, a significant health concern in China. In addition to Xin Ao Xing, Biostar offers 12 other OTC products and 17 prescription-based pharmaceuticals, catering to a broad spectrum of healthcare needs. Biostar's OTC product line includes Ganwang compound paracetamol and amantadine hydrochloride capsule for cold and flu symptoms, Tianqi Dysmenorrhea capsule for menstrual pain, Deafness Tongqiao pills for ear-related issues, Wenweishu capsules for chronic gastritis, Zhitongtougu ointment for joint pain, and Chuzhang Zehaifu tablets for cataract. The company's prescription drugs cover areas such as cardiovascular health (Danshen granules and tablets), pediatric care (Taohuasan), and various other conditions including rhinitis, hyperthyroidism, and bacterial infections. Biostar also operates an online platform, the China Hepatitis Internet hospital, providing information and treatment options for HBV patients, as well as facilitating the purchase of HBV medicines. The company distributes its products through a network of distributors and sales personnel, reaching approximately 28 provinces across China.
Qué hacen
- Develops over-the-counter (OTC) pharmaceutical products.
- Manufactures prescription pharmaceutical products.
- Markets pharmaceutical products for various diseases and conditions.
- Offers Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B.
- Provides traditional Chinese medicines.
- Operates an online platform for HBV patients.
Modelo de Negocio
- Develops and manufactures OTC and prescription pharmaceutical products.
- Sells products through distributors and a network of sales people in China.
- Operates an online platform (China Hepatitis Internet hospital) for HBV patients.
- Generates revenue from the sale of pharmaceutical products.
Contexto de la Industria
Biostar Pharmaceuticals operates within the Chinese pharmaceutical market, a large and rapidly growing sector driven by increasing healthcare expenditure and an aging population. The market is characterized by a mix of domestic and international players, with a growing demand for both OTC and prescription drugs. Biostar competes with other generic drug manufacturers, including BIOCQ, CLVR, CRFTF, CWWBF, and ELOX, as well as larger multinational pharmaceutical companies. The company's focus on traditional Chinese medicine and its established distribution network provide a competitive advantage in certain segments of the market.
Clientes Clave
- Patients in China seeking OTC medications for common ailments.
- Patients in China requiring prescription medications for various diseases.
- Hospitals and clinics in China that purchase pharmaceutical products.
- Distributors who sell Biostar's products to pharmacies and other retailers.
Finanzas
Gráfico e información
Precio de la acción de Biostar Pharmaceuticals, Inc. (BSPM): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BSPM.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BSPM.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BSPM.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BSPM en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Ronghua Wang
CEO
Ronghua Wang serves as the CEO of Biostar Pharmaceuticals, Inc. He is responsible for managing the company's overall operations and strategic direction. His background includes experience in the pharmaceutical industry, with a focus on sales and marketing. He has been instrumental in expanding the company's distribution network and product portfolio. He oversees a workforce of approximately 200 employees.
Historial: Under Ronghua Wang's leadership, Biostar Pharmaceuticals has focused on developing and marketing pharmaceutical products in China. Key milestones include the expansion of the company's OTC product line and the establishment of the China Hepatitis Internet hospital. However, the company's financial performance, as indicated by its negative profit margin, remains a challenge.
Información del mercado OTC de BSPM
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biostar Pharmaceuticals may not meet the listing requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as exchange-listed companies. This can result in increased risks for investors due to the potential for less transparency and greater information asymmetry. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Determine the company's ownership structure and potential conflicts of interest.
- Check for any history of fraud or regulatory violations.
- Consult with a financial advisor before investing.
- Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
BSPM Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar BSPM?
Biostar Pharmaceuticals, Inc. (BSPM) actualmente tiene una puntuación IA de 47/100, indicando puntuación baja. Fortaleza clave: Established distribution network in China.. Riesgo principal a monitorear: Potential: Competition from larger pharmaceutical companies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BSPM?
BSPM actualmente puntúa 47/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BSPM?
Los precios de BSPM se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BSPM?
La cobertura de analistas para BSPM incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BSPM?
Las categorías de riesgo para BSPM incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from larger pharmaceutical companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BSPM?
La relación P/E para BSPM compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BSPM sobrevalorada o infravalorada?
Determinar si Biostar Pharmaceuticals, Inc. (BSPM) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BSPM?
Biostar Pharmaceuticals, Inc. (BSPM) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is limited and may not be fully up-to-date.
- OTC stocks carry higher risks than exchange-listed stocks.